FDA Approves Adrabetadex as First Therapy Shown to Improve Survival in Infantile-Onset Niemann-Pick Disease Type C

Author profile image Aggregator
0 comments
The FDA approved Beren Therapeutics' adrabetadex, marketed as Lembaz, to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C.

Source: NeurologyLive Published 17 Nov 2026 Imported 17 Nov 2026 Relevancy: Not reviewed

Read the article